Zanolimumab (HuMax-CD4®), a fully human monoclonal antibody in clinical development for cutaneous T-cell lymphoma


https://doi.org/10.4081/hmr.v2i5.736
Vol. 2 No. 5: New Drugs in Hematology, Bologna, Italy 5-7 October 2008
Published: June 23, 2009
Abstract Views: 243
PDF: 315
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Zanolimumab (HuMax-CD4®; Genmab, Copenhaven, Denmark) is a monoclonal human anti-CD4 antibody and specifically targets Thelper cells as well as CD4+ CTCL tumor cells and at a lower level monocytes and macrophages. Due to the interference with the interaction of the CD4 antigen and the major histocompatibility complex class II-molecule (MHC-II) this antibody is decreasing T-cell activation. In 2 phase II multicenter, prospective, open-label clinical trials the efficiency and safety of this anti-CD4 antibody was determined in relapsed early and advanced staged CTCL patients. 38 patients with MF and 9 patients with SS were treated intravenously with zanolimumab at a dosage of 280 mg or 560 mg for early stage patients and with 280 mg or 980 mg for advanced stage patients.

Supporting Agencies


Assaf, C. (2009). Zanolimumab (HuMax-CD4®), a fully human monoclonal antibody in clinical development for cutaneous T-cell lymphoma. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.736
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC